Advances in antisense oligonucleotide treatment for cancer
Japanese Journal of Clinical Oncology · 07.05.2026 · 56 (5) · 503-517
DOI: 10.1093/jjco/hyag017 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 03.02.2026. Verfasst von Lu Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer RNA Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Molecular Targeted Therapy, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Takeda Science Foundation.
Abstract (Originalsprache)
RNA therapeutics, including antisense oligonucleotides (ASOs), have emerged as a promising class of drugs, with several already approved for clinical use. To date, most approved ASO-based RNA therapies target non-malignant disorders such as neurodegenerative diseases, and only a single therapy in this class has been approved for cancer. Notably, nearly half of existing RNA therapeutics act by modulating RNA splicing. Given the growing evidence implicating aberrant RNA splicing in cancer pathogenesis, the development of ASO-based therapeutics for oncologic indications is expected to accelerate. More than 250 clinical trials have evaluated oligonucleotide agents targeting diverse cancer-associated molecules, with several showing encouraging early results. In this review, we summarize recent advances in understanding cancer biology relevant to ASO-based therapies and highlight ongoing progress in the development of RNA-targeted approaches for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer RNA Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
- Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
- Department of Cancer Cellular Signaling, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
- Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.
ORCID-Profile: Lu Zhu, Pariha Muhtar, Susumu Goyama, Akihide Yoshimi
Förderung
- Japan Agency for Medical Research and Development
- Takeda Science Foundation
Zitieren
APA
Zhu, L., Muhtar, P., Goyama, S., & Yoshimi, A. (2026). Advances in antisense oligonucleotide treatment for cancer. Japanese Journal of Clinical Oncology, 56(5), 503-517. https://doi.org/10.1093/jjco/hyag017
Vancouver
Zhu L, Muhtar P, Goyama S, Yoshimi A. Advances in antisense oligonucleotide treatment for cancer. Japanese Journal of Clinical Oncology. 2026;56(5):503-517. doi:10.1093/jjco/hyag017
BibTeX
@article{Zhu2026,
author = {Zhu, Lu and Muhtar, Pariha and Goyama, Susumu and Yoshimi, Akihide},
title = {Advances in antisense oligonucleotide treatment for cancer},
journal = {Japanese Journal of Clinical Oncology},
year = {2026},
volume = {56},
number = {5},
pages = {503--517},
doi = {10.1093/jjco/hyag017}
}
EUVIMED